- Home
- QFIN vs GH Comparison
QFIN vs GH Comparison
Compare QFIN & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QFIN | GH |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 12.7B |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | QFIN | GH |
|---|---|---|
| Price | $11.66 | $118.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 19 |
| Target Price | $22.20 | ★ $119.79 |
| AVG Volume (30 Days) | 980.8K | ★ 1.9M |
| Earning Date | 05-18-2026 | 05-07-2026 |
| Dividend Yield | ★ 12.36% | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $982,021,000.00 |
| Revenue This Year | N/A | $33.30 |
| Revenue Next Year | N/A | $28.27 |
| P/E Ratio | $2.21 | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $12.12 | $37.73 |
| 52 Week High | $46.18 | $121.01 |
Technical Indicators
Market Signals| Indicator | QFIN | GH |
|---|---|---|
| Relative Strength Index (RSI) | 33.30 | 77.61 |
| Support Level | N/A | $97.16 |
| Resistance Level | $14.36 | N/A |
| Average True Range (ATR) | 0.45 | 5.99 |
| MACD | -0.13 | 2.78 |
| Stochastic Oscillator | 11.90 | 94.08 |
Price Performance
Historical ComparisonAbout QFIN Qifu Technology Inc.
Qfin Holdings Inc is engaged in matching individual borrowers with credit demand to a diversified pool of financial institutions with credit to supply through a financial technology platform. It has released large-scale financial credit multimodal benchmark, building a critical bridge between credit AI research and real-world applications.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.